Synopsis
Synopsis
0
USDMF
0
KDMF
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aparsonin
2. Bc, Bromhexin
3. Bisolvon
4. Bromhexin
5. Bromhexin Bc
6. Bromhexin Berlin Chemie
7. Bromhexin Berlin-chemie
8. Bromhexin Berlinchemie
9. Bromhexin Ratiopharm
10. Bromhexin Von Ct
11. Bromhexin-ratiopharm
12. Bromhexine
13. Bromhexine Monohydrochloride
14. Bromhexine, Famel
15. Bromhexinratiopharm
16. Brotussol
17. Ct, Bromhexin Von
18. Darolan
19. Dur Elix
20. Dur-elix
21. Durelix
22. Famel Bromhexine
23. Flegamin
24. Flubron
25. Hustentabs Ratiopharm
26. Hustentabs-ratiopharm
27. Hustentabsratiopharm
28. Hydrochloride, Bromhexine
29. Monohydrochloride, Bromhexine
30. Mucohexine
31. Na 274
32. Na-274
33. Na274
34. Quentan
35. Tesacof
36. Von Ct, Bromhexin
1. 611-75-6
2. Bromhexine Hcl
3. Bisolvon
4. Auxit
5. Bromohexine Hydrochloride
6. Bromhexine (hydrochloride)
7. Broncokin
8. Viscolyt
9. 2,4-dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline Hydrochloride
10. Bromhexine Chloride
11. Bromohexine Monohydrochloride
12. Na 274
13. Bromehexine Hydrochloride
14. Mfcd00056626
15. Yc2zom3z8v
16. Nsc-758383
17. Chebi:31303
18. N-cyclohexyl-n-methyl-(2-amino-3,5-dibromobenzyl)ammonium Chloride
19. Na-274
20. 611-75-6 (hcl)
21. Ncgc00095005-01
22. 2-amino-3,5-dibromo-n-cyclohexyl-n-methylbenzylamine Hydrochloride
23. 2-amino-n-cyclohexyl-3,5-dibromo-n-methylbenzylamine Hydrochloride
24. N-(2-amino-3,5-dibromobenzyl)-n-methyl-cyclohexylammonium Chloride
25. 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline Hydrochloride
26. Benzenemethanamine, 2-amino-3,5-dibromo-n-cyclohexyl-n-methyl-, Monohydrochloride
27. Dsstox_cid_25886
28. Dsstox_rid_81200
29. Dsstox_gsid_45886
30. Bromessina
31. Lisomucin
32. Quentan
33. 2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline;hydrochloride
34. Cas-611-75-6
35. Bromessina [italian]
36. Bromihexine Hydrochloride
37. Unii-yc2zom3z8v
38. Ophtolsol
39. Sr-05000001825
40. Bisolvon (tn)
41. Einecs 210-280-8
42. Bromhexine Hydrochloride [usan:jan]
43. Brombenzonium
44. Schembl99613
45. Bromohexine Hydrochloride,(s)
46. Spectrum1503107
47. Chembl1319139
48. Dtxsid0045886
49. Bromhexine For System Suitability
50. Hy-b0372a
51. Hms1922e19
52. Pharmakon1600-01503107
53. Tox21_111385
54. Bromhexine Hydrochloride [mi]
55. Ccg-39304
56. N-(2-amino-3,5-dibromobenzyl)-n-methylcyclohexylamine Hydrochloride
57. Nsc758383
58. S2060
59. Bromhexine Hydrochloride [jan]
60. Akos015906433
61. Benzylamine, 2-amino-n-cyclohexyl-3,5-dibromo-n-methyl-, Hydrochloride
62. Tox21_111385_1
63. Ac-6857
64. Bromhexine Hydrochloride (jp17/usan)
65. Bromhexine Hydrochloride [usan]
66. Ks-5253
67. Nsc 758383
68. Bromhexine Hydrochloride [mart.]
69. Bromhexine Hydrochloride [who-dd]
70. Ncgc00095005-02
71. Ncgc00178520-03
72. 3,5-dibromo-n(sup Alpha)-cyclohexyl-n(sup Alpha)-methyltoluene-alpha,2-diamine Monohydrochloride
73. Sy046825
74. Bromhexine Hydrochloride, >=98.0% (at)
75. B4054
76. Bromhexine Hydrochloride, Analytical Standard
77. Ft-0603492
78. Sw199599-2
79. Bromhexine Hydrochloride [ep Monograph]
80. D01778
81. D70838
82. 611b756
83. A833075
84. Q-200754
85. Sr-05000001825-2
86. Q27114269
87. Bromhexine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
88. 2,4-dibromo-6-((cyclohexyl(methyl)amino)methyl)anilinehydrochloride
89. N-(2-amino-3,5-dibromobenzyl)-n-methylcyclohexanaminium Chloride
90. Bromhexine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
91. 3,5-dibromo-n(alpha)-cyclohexyl-n(alpha)-methyltoluene-alpha,2-diamine Monohydrochloride
92. Bromhexine For System Suitability, European Pharmacopoeia (ep) Reference Standard
93. Bromhexine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
94. 2-amino-3,5-dibromo-n-cyclohexyl-n-methylbenzylamine Hydrochloride, N-(2-amino-3,5-dibromobenzyl)-n-methylcyclohexylamine Hydrochloride
95. 3,5-dibromo-n(sup .alpha.)-cyclohexyl-n(sup .alpha.)-methyltoluene-.alpha.,2-diamine Monohydrochloride
96. Toluene-alpha,2-diamine, 3,5-dibromo-n(sup Alpha)-cyclohexyl-n-(sup Alpha)-methyl-, Monohydrochloride
| Molecular Weight | 412.59 g/mol |
|---|---|
| Molecular Formula | C14H21Br2ClN2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 411.97395 g/mol |
| Monoisotopic Mass | 409.97600 g/mol |
| Topological Polar Surface Area | 29.3 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 256 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
22
PharmaCompass offers a list of Bromhexine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bromhexine Hydrochloride manufacturer or Bromhexine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bromhexine Hydrochloride manufacturer or Bromhexine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Bromhexine Hydrochloride API Price utilized in the formulation of products. Bromhexine Hydrochloride API Price is not always fixed or binding as the Bromhexine Hydrochloride Price is obtained through a variety of data sources. The Bromhexine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Auxit manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Auxit, including repackagers and relabelers. The FDA regulates Auxit manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Auxit API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Auxit manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Auxit supplier is an individual or a company that provides Auxit active pharmaceutical ingredient (API) or Auxit finished formulations upon request. The Auxit suppliers may include Auxit API manufacturers, exporters, distributors and traders.
click here to find a list of Auxit suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Auxit Drug Master File in Japan (Auxit JDMF) empowers Auxit API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Auxit JDMF during the approval evaluation for pharmaceutical products. At the time of Auxit JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Auxit suppliers with JDMF on PharmaCompass.
A Auxit CEP of the European Pharmacopoeia monograph is often referred to as a Auxit Certificate of Suitability (COS). The purpose of a Auxit CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Auxit EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Auxit to their clients by showing that a Auxit CEP has been issued for it. The manufacturer submits a Auxit CEP (COS) as part of the market authorization procedure, and it takes on the role of a Auxit CEP holder for the record. Additionally, the data presented in the Auxit CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Auxit DMF.
A Auxit CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Auxit CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Auxit suppliers with CEP (COS) on PharmaCompass.
A Auxit written confirmation (Auxit WC) is an official document issued by a regulatory agency to a Auxit manufacturer, verifying that the manufacturing facility of a Auxit active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Auxit APIs or Auxit finished pharmaceutical products to another nation, regulatory agencies frequently require a Auxit WC (written confirmation) as part of the regulatory process.
click here to find a list of Auxit suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Auxit as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Auxit API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Auxit as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Auxit and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Auxit NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Auxit suppliers with NDC on PharmaCompass.
Auxit Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Auxit GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Auxit GMP manufacturer or Auxit GMP API supplier for your needs.
A Auxit CoA (Certificate of Analysis) is a formal document that attests to Auxit's compliance with Auxit specifications and serves as a tool for batch-level quality control.
Auxit CoA mostly includes findings from lab analyses of a specific batch. For each Auxit CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Auxit may be tested according to a variety of international standards, such as European Pharmacopoeia (Auxit EP), Auxit JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Auxit USP).
